Press Releases
Future press releases will be published here.
The rapidly expanding market of approaches to treat obesity and related metabolic diseases demands next-generation solutions to the unmet needs such as poor tolerability, high patient burden and lack of disease modification, which leads to low adherence and limits sustainable weight management and outcomes benefit.
At Alveus Therapeutics, we are building a differentiated therapeutic portfolio driven by one goal: bringing meaningful innovation to patients. Our approach combines strong genetic data, deep biological and clinical expertise, and rigorous program selection. We focus on targets with well-established human validation and clear mechanistic rationales to develop first- or best-in-class molecules that deliver transformative benefits in the evolving obesity treatment landscape.
More about ALV-100Our leadership team brings proven success in metabolic disease drug development and pipeline building, backed by a Board with expertise across critical functional areas.
Get to know our teamAlveus's pipeline is focused on next-generation metabolic therapies; the lead asset is currently in Phase 2.
About our pipelineFuture press releases will be published here.